EVRS awards intraocular surgery simulator developers

Article

Markus Schill, PhD and Clemens Wagner, PhD of VRMagic GmbH have received the European VitreoRetinal Society's annual Relja Zivojnovic Award for outstanding contributions to the field of vitreoretinal surgery.

Markus Schill, PhD and Clemens Wagner, PhD of VRMagic GmbH have received the European VitreoRetinal Society's annual Relja Zivojnovic Award for outstanding contributions to the field of vitreoretinal surgery. The award was conferred in recognition of the virtual reality ocular surgery simulator, EYESi, that Dr Schill and Dr Wagner developed to enable surgeons to broaden their experience and practice and refine techniques for vitreoretinal surgery without endangering patient safety or comfort.

The EYESi machine - developed by a team of scientists led by Dr Schill and Dr Wagner at the University of Mannheim, Germany - was launched in 2001 to coincide with the establishment of VRMagic, the company formed by seven of the scientists involved in the creation of the EYESi. The training platform allows surgeons to practice techniques under uniform conditions, but can also be adjusted for individual needs. The machine, which can also be used for cataract surgery training, is now available around the world.

The award was presented during a ceremony held on September 8 during the EVRS annual meeting, held this year in Prague, the Czech Republic.

From left to right: Dr Klaus Lucke, Vice President EVRS, Dr Markus Schill and Dr Clemens Wagner, VRmagic, at the award ceremony in Prague on the 8th September 2008.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.